PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 9167024-0 1997 In vitro inhibition of heparin-induced platelet aggregation in plasma from patients with HIT by SR 121566, a newly developed Gp IIb/IIIa antagonist. Heparin 23-30 integrin subunit alpha 2b Homo sapiens 125-131 9013915-12 1997 Clinical trials are warranted to assess whether GP IIb/IIIa antagonists may allow patients with HAAb to safely receive heparin. Heparin 119-126 integrin subunit alpha 2b Homo sapiens 48-54 7843648-2 1994 An ELISA was developed for directly measuring the expression of glycoprotein IIb/IIIa (GPIIb/IIIa) on platelets in the presence and absence of ADP and under the influence of various heparins. Heparin 182-190 integrin subunit alpha 2b Homo sapiens 87-97 8589205-10 1995 The activation of GP IIb-IIIa occurred despite the patients receiving aspirin and heparin. Heparin 82-89 integrin subunit alpha 2b Homo sapiens 18-24 7843648-4 1994 Heparin also induced the expression of GPIIb/IIIa without prior stimulation with ADP. Heparin 0-7 integrin subunit alpha 2b Homo sapiens 39-44 7843648-6 1994 These results suggested that heparin(oid)s modulate the expression of GPIIb/IIIa with ADP as a mediator, and that protamine sulfate is contraindicated as an antidote in heparin-induced thrombocytopenia. Heparin 29-36 integrin subunit alpha 2b Homo sapiens 70-75 2806479-6 1989 These combined results suggest the participation of GP IIb/IIIa but not GP Ib in heparin-induced platelet aggregation. Heparin 81-88 integrin subunit alpha 2b Homo sapiens 52-58 8361901-4 1993 The authors suggest that such a course of this interaction results from the stimulating action of heparin added in adequate concentration on protein release from platelet alpha granulations--which bound GP II b/III a complex with collagen. Heparin 98-105 integrin subunit alpha 2b Homo sapiens 203-210 1329249-0 1992 Heparin potentiation of collagen-induced platelet aggregation is related to the GPIIb/GPIIIa receptor and not to the GPIb receptor, as tested by whole blood aggregometry. Heparin 0-7 integrin subunit alpha 2b Homo sapiens 80-85 1329249-8 1992 In conclusion, the potentiation of collagen-induced platelet aggregation by heparin was not inhibited by MAb 7E3, RGDS, aurin or MAb 6D1, but was abolished by MAb 10E5, implying that the heparin effect is related to activation of the platelet GP IIb/IIIa receptor complex. Heparin 76-83 integrin subunit alpha 2b Homo sapiens 243-249 28377232-11 2017 More patients received GPIIb/IIIa antagonist in the UFH group (30% vs. 3%; p <0.001). Heparin 52-55 integrin subunit alpha 2b Homo sapiens 23-28 24273488-5 2013 RESULTS: Compared to control cultures, the 5-factor combination with heparin induced significantly (p <= 0.05) higher numbers of: CFU-MKs and CD41+ cells on days 7 and 14; CD41+ cells displaying hyperploidy levels (>=8N) on day 14; platelets on day 14. Heparin 69-76 integrin subunit alpha 2b Homo sapiens 145-149 26266343-6 2015 Meta-regression analyses demonstrated that additional administration of GP IIb/IIIa receptor inhibitors (P = 0.01), especially eptifibatide (P = 0.001) and tirofiban (P = 0.002), was likely to increase the major bleeding risk associated with bivalirudin.Bivalirudin, in comparison to heparin, is associated with a markedly lower risk of major bleeding, and the additional use of GP IIb/IIIa inhibitors may weaken this benefit. Heparin 284-291 integrin subunit alpha 2b Homo sapiens 72-78 26102015-10 2015 There may be reinforcement in the sole utilization of heparin confining GP IIb/IIIa inhibitors and other intravenous antithrombotics to bailout therapy for periprocedural PCI complications in acute coronary syndrome patients." Heparin 54-61 integrin subunit alpha 2b Homo sapiens 72-78 27583038-10 2016 There may be reinforcement in the sole utilization of heparin confining GP IIb/IIIa inhibitors and other intravenous antithrombotics to bailout therapy for periprocedural PCI complications in AMI patients". Heparin 54-61 integrin subunit alpha 2b Homo sapiens 72-78 25389143-6 2014 In the mixed treatment comparison models, when compared with unfractionated heparin plus GpIIb/IIIa inhibitor, unfractionated heparin was associated with a higher risk of major adverse cardiovascular events (relative risk 1.49 (95% confidence interval 1.21 to 1.84), as were bivalirudin (relative risk 1.34 (1.01 to 1.78)) and fondaparinux (1.78 (1.01 to 3.14)). Heparin 126-133 integrin subunit alpha 2b Homo sapiens 89-94 24273488-5 2013 RESULTS: Compared to control cultures, the 5-factor combination with heparin induced significantly (p <= 0.05) higher numbers of: CFU-MKs and CD41+ cells on days 7 and 14; CD41+ cells displaying hyperploidy levels (>=8N) on day 14; platelets on day 14. Heparin 69-76 integrin subunit alpha 2b Homo sapiens 175-179 22294539-5 2012 This case report describes first time use of GP IIb/IIIa inhibitor and IABP with heparin, in a patient just after spinal surgery. Heparin 81-88 integrin subunit alpha 2b Homo sapiens 45-51 18484795-2 2008 Intravenous GP IIb/IIIa antagonists abciximab, tirofiban and eptifibatide have demonstrated efficacy in acute coronary syndromes when combined with heparin, aspirin, clopidogrel and percutanous coronary interventions. Heparin 148-155 integrin subunit alpha 2b Homo sapiens 12-18 21060749-6 2010 Thrombolysis In Myocardial Infarction (TIMI) with major bleeding was observed in LMHW and UFH with Gp IIb/IIIa inhibitor (1/219 [0.5%] vs 1/257 [0.4%], P=1.00). Heparin 90-93 integrin subunit alpha 2b Homo sapiens 99-105 21060749-7 2010 For patients with STEMI managed with a primary PCI and Gp IIb/IIIa inhibitor, LMWH is more beneficial than UFH. Heparin 107-110 integrin subunit alpha 2b Homo sapiens 55-61 24323522-0 2010 A Pilot Trial of Low-Dose Intravenous Abciximab and Unfractionated Heparin for Acute Ischemic Stroke: Translating GP IIb/IIIa Receptor Inhibition to Clinical Practice. Heparin 67-74 integrin subunit alpha 2b Homo sapiens 114-120 18579401-0 2008 Heparin-induced thrombocytopenia and cardiopulmonary bypass: anticoagulation with unfractionated heparin and the GPIIb/IIIa inhibitor tirofiban and successful use of rFVIIa for post-protamine bleeding due to persistent platelet blockade. Heparin 0-7 integrin subunit alpha 2b Homo sapiens 113-118 15624282-7 2004 Administration of GpIIb/IIIa in addition to thrombolytics, aspirin and heparin was associated with a significant reduction in the combined criteria by 17% (95% CI: 10% - 23%) and a significant excess of major bleeding by 69% (95% CI: 38% - 109%). Heparin 71-78 integrin subunit alpha 2b Homo sapiens 18-23 16765113-6 2006 This difference was ameliorated when GP IIb/IIIa inhibitors were used consistently in a previous trial that compared bivalirudin with heparin during PCI (4.6% vs 6.7%, p=0.322). Heparin 134-141 integrin subunit alpha 2b Homo sapiens 37-43 16683212-11 2006 CONCLUSIONS: In routine clinical practice, patients treated with GP IIb/IIIa inhibitors have slightly improved outcomes and similar bleeding risks with LMWH than with UFH. Heparin 167-170 integrin subunit alpha 2b Homo sapiens 65-71 16079449-9 2005 A trend towards statistical significance was observed in the 6-month secondary re-intervention and limb salvage rates (10.7% versus 18.8%; p = 0.0501 and 93.9% versus 88.5%; p = 0.053) in the DTI-GP IIb-IIIa versus the UFH group, respectively. Heparin 219-222 integrin subunit alpha 2b Homo sapiens 196-202 17540196-10 2007 Patients older than 75 years who received GP IIb/IIIa antagonists and any antithrombotic but not PCI had an increased risk of major bleeding (LMWH 14%, UFH 8.3%). Heparin 152-155 integrin subunit alpha 2b Homo sapiens 42-48 17476038-7 2007 Patients treated with heparin were significantly more likely to be treated with GP IIb/IIIa inhibitors (91% vs 25%; p = 0.001). Heparin 22-29 integrin subunit alpha 2b Homo sapiens 80-86 17039513-0 2007 Platelet GPIIb/IIIa antagonist, XV459, in heparin-induced thrombocytopenia. Heparin 42-49 integrin subunit alpha 2b Homo sapiens 9-14 17039513-5 2007 In this study, the ability of a novel platelet GPIIb/IIIa antagonist, a free acid form of roxifiban (XV459), to block platelet activation/aggregation in response to highly characterized heparin-PF4 antibody-positive plasma/heparin was examined using light transmittance aggregometry, serotonin release, and (125)I-fibrinogen binding assays to human platelets. Heparin 186-193 integrin subunit alpha 2b Homo sapiens 47-52 17039513-9 2007 The platelet GPIIb/IIIa receptor antagonist (XV459) might be of potential benefit in the management of thrombotic thrombocytopenia produced by heparin and/or related glycosaminoglycans. Heparin 143-150 integrin subunit alpha 2b Homo sapiens 13-18 17102832-1 2006 BACKGROUND: Heparin with adjunctive glycoprotein IIb/IIIa platelet receptor (GP IIb/IIIa) inhibitors has demonstrated its effectiveness in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). Heparin 12-19 integrin subunit alpha 2b Homo sapiens 77-83 16637790-7 2006 In the base-case analysis, the use of bivalirudin with provisional GP IIb-IIIa inhibitor therapy dominated the UFH and planned GP IIb-IIIa inhibitor approach: UFH with eptifibatide was 74 US dollars more expensive and 1.2% less effective, and UFH with abciximab was 777 US dollars more expensive and 2.3% less effective. Heparin 159-162 integrin subunit alpha 2b Homo sapiens 127-133 16637790-7 2006 In the base-case analysis, the use of bivalirudin with provisional GP IIb-IIIa inhibitor therapy dominated the UFH and planned GP IIb-IIIa inhibitor approach: UFH with eptifibatide was 74 US dollars more expensive and 1.2% less effective, and UFH with abciximab was 777 US dollars more expensive and 2.3% less effective. Heparin 159-162 integrin subunit alpha 2b Homo sapiens 127-133 15085057-4 2004 Especially the additional value of GP IIb/IIIa inhibition on top of an aggressive antithrombotic therapy (including aspirin, heparins, and clopidogrel) requires further clarification. Heparin 125-133 integrin subunit alpha 2b Homo sapiens 35-41 15201252-6 2004 Coadministration of heparin with Gp IIb/IIIa blockers provides improved protection against persistent platelet activation, thereby improving outcome after percutaneous coronary intervention. Heparin 20-27 integrin subunit alpha 2b Homo sapiens 33-39 15457395-11 2004 In case of pre-interventional application of the GP IIb/IIIa receptor inhibitor 22.3 % of patients revealed normal (TIMI-3) flow of the IRA before PCI, compared to 14.9 % TIMI-3 flow with 5000 IE Heparin/500 mg aspirin alone (p < 0.05). Heparin 196-203 integrin subunit alpha 2b Homo sapiens 49-55 12919181-1 2003 AIMS: To investigate the pharmacodynamic interaction of unfractionated heparin (UFH) and acetylic salicylic acid (ASA) on YM337, a monoclonal humanized antibody of the platelet GPIIb/IIIa receptor. Heparin 71-78 integrin subunit alpha 2b Homo sapiens 177-182 12919181-1 2003 AIMS: To investigate the pharmacodynamic interaction of unfractionated heparin (UFH) and acetylic salicylic acid (ASA) on YM337, a monoclonal humanized antibody of the platelet GPIIb/IIIa receptor. Heparin 80-83 integrin subunit alpha 2b Homo sapiens 177-182 12943500-3 2003 Low molecular weight heparins (LMWH) have several advantages over UF heparin therapy, making them attractive alternatives for use in combination with GP IIb/IIIa inhibitors. Heparin 21-29 integrin subunit alpha 2b Homo sapiens 150-156 14728074-12 2003 CONCLUSION: The GP IIb/IIIa receptor antagonist abciximab, when used with aspirin and heparin, has demonstrated efficacy in reducing the short- and long-term risk of ischemic complications in patients with ischemic heart disease undergoing percutaneous coronary intervention, when used with aspirin and heparin. Heparin 86-93 integrin subunit alpha 2b Homo sapiens 16-22 12877649-0 2003 Can bivalirudin and provisional GP IIb/IIIa blockade REPLACE heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention? Heparin 61-68 integrin subunit alpha 2b Homo sapiens 32-38 12678189-8 2003 During medication with GP IIb/IIIa inhibitor, the patients received a reduced heparin dosage for 24 hours. Heparin 78-85 integrin subunit alpha 2b Homo sapiens 23-29 12626998-10 2003 MEASUREMENTS AND MAIN RESULTS: Expression of GP IIb-IIIa and P-selectin on adenosine diphosphate-activated platelets and platelet-leukocyte aggregation were significantly lower after the passage of blood through the hemofilter in patients receiving an extracorporeal infusion of prostacyclin plus heparin when compared with control patients receiving heparin only. Heparin 297-304 integrin subunit alpha 2b Homo sapiens 45-51 12626998-10 2003 MEASUREMENTS AND MAIN RESULTS: Expression of GP IIb-IIIa and P-selectin on adenosine diphosphate-activated platelets and platelet-leukocyte aggregation were significantly lower after the passage of blood through the hemofilter in patients receiving an extracorporeal infusion of prostacyclin plus heparin when compared with control patients receiving heparin only. Heparin 351-358 integrin subunit alpha 2b Homo sapiens 45-51 14728074-12 2003 CONCLUSION: The GP IIb/IIIa receptor antagonist abciximab, when used with aspirin and heparin, has demonstrated efficacy in reducing the short- and long-term risk of ischemic complications in patients with ischemic heart disease undergoing percutaneous coronary intervention, when used with aspirin and heparin. Heparin 303-310 integrin subunit alpha 2b Homo sapiens 16-22 10502232-2 1999 Studies in patients scheduled for percutaneous coronary intervention and those with unstable angina or non-Q-wave myocardial infarction have shown that a combination of intravenous GP IIb-IIIa inhibitors with aspirin and heparin is associated with a reduction in death or myocardial infarction compared with therapy with aspirin and heparin alone. Heparin 333-340 integrin subunit alpha 2b Homo sapiens 181-187 11560562-1 2001 AIMS: The objective of our study was to define the interaction between either unfractionated heparin (UFH) or a low molecular weight heparin, reviparin (REV), and the pharmacodynamic profile of the GPIIb/IIIa-antagonists abciximab (ABC) or tirofiban (T). Heparin 93-100 integrin subunit alpha 2b Homo sapiens 198-203 11560562-1 2001 AIMS: The objective of our study was to define the interaction between either unfractionated heparin (UFH) or a low molecular weight heparin, reviparin (REV), and the pharmacodynamic profile of the GPIIb/IIIa-antagonists abciximab (ABC) or tirofiban (T). Heparin 102-105 integrin subunit alpha 2b Homo sapiens 198-203 11560562-1 2001 AIMS: The objective of our study was to define the interaction between either unfractionated heparin (UFH) or a low molecular weight heparin, reviparin (REV), and the pharmacodynamic profile of the GPIIb/IIIa-antagonists abciximab (ABC) or tirofiban (T). Heparin 133-140 integrin subunit alpha 2b Homo sapiens 198-203 11565896-8 2001 An 80% blockage of the GPIIb/IIIa receptors and suppression of platelet aggregation to less than 20% allows the giving of unfractionated heparin and running CPB in a standard fashion despite HIT and thrombosis. Heparin 137-144 integrin subunit alpha 2b Homo sapiens 23-28 11286313-3 2001 There are theoretical grounds to expect LMWHs to be more effective than unfractionated heparin (UFH) in combination with GP IIb/IIIa inhibitors, since UFH, but not LMWH, activates platelets. Heparin 151-154 integrin subunit alpha 2b Homo sapiens 121-127 10974231-3 2000 RESULTS: A significantly higher IC50s was shown with heparin (free ionized calcium=1.1 mM) as compared to that with citrate (free ionized calcium=0.12 mM) with class II GPIIb/IIIa antagonists (P<0.01) such as Orbofiban, and Integrilin. Heparin 53-60 integrin subunit alpha 2b Homo sapiens 169-174 10731377-6 2000 Several clinical trials in the past few years have documented the beneficial value of GP IIb/IIIa inhibitors in patients treated with aspirin and heparin, with a significant reduction in the cumulative end-point of death and/or myocardial infarction at 48-96 hours (odds ratio--OR 0.81, 95% confidence interval--CI 0.71-0.92, p < 0.01). Heparin 146-153 integrin subunit alpha 2b Homo sapiens 86-92 14529393-4 2003 Despite of the success of intravenous acute GPIIb/IIIa blockade when given in conjunction with heparin, chronic oral GPIIb/IIIa antagonists with or without aspirin failed in various cardiovascular settings. Heparin 95-102 integrin subunit alpha 2b Homo sapiens 44-49 12749745-12 2003 CONCLUSION: The GP IIb/IIIa receptor antagonist abciximab, when used with aspirin and heparin, has demonstrated efficacy in reducing the short- and long-term risk of ischaemic complications in patients with ischaemic heart disease undergoing percutaneous coronary intervention, when used with aspirin and heparin. Heparin 86-93 integrin subunit alpha 2b Homo sapiens 16-22 12749745-12 2003 CONCLUSION: The GP IIb/IIIa receptor antagonist abciximab, when used with aspirin and heparin, has demonstrated efficacy in reducing the short- and long-term risk of ischaemic complications in patients with ischaemic heart disease undergoing percutaneous coronary intervention, when used with aspirin and heparin. Heparin 305-312 integrin subunit alpha 2b Homo sapiens 16-22 11560562-13 2001 CONCLUSIONS: Co-medication with UFH attenuated platelet inhibition during treatment with GPIIb/IIIa-antagonists, but these effects were not seen with the low molecular weight heparin reviparin. Heparin 32-35 integrin subunit alpha 2b Homo sapiens 89-94 11560299-3 2001 Abciximab and heparin were administered according to guidelines of the Evaluation of PTCA [percutaneous transluminal coronary angioplasty] to Improve Long-Term Outcome With Abciximab GP IIb/IIIa Blockade (EPILOG). Heparin 14-21 integrin subunit alpha 2b Homo sapiens 183-189 11019977-7 2000 At high pharmacologic concentrations, unfractionated heparin and enoxaparin, but not hirudin, further reduced factor V/Va binding to the surface of activated platelets in the presence of GPIIb-IIa antagonists. Heparin 53-60 integrin subunit alpha 2b Homo sapiens 187-192 10793178-7 2000 GP IIb/IIIa inhibitors have been shown to improve angiographic Thrombolysis in Myocardial Infarction (TIMI) 3 flow rates when used as reperfusion therapy given with heparin and aspirin as compared with heparin and aspirin alone. Heparin 165-172 integrin subunit alpha 2b Homo sapiens 0-6 10735780-4 2000 Unfractionated heparin increased adenosine diphosphate-induced expression of P-selectin and GP IIb-IIIa in a dose-dependent manner. Heparin 15-22 integrin subunit alpha 2b Homo sapiens 92-98 10735780-8 2000 In contrast, protamine antagonized the effect of heparin on GP IIb-IIIa expression but potentiated the effect of heparin on P-selectin expression. Heparin 49-56 integrin subunit alpha 2b Homo sapiens 60-66 10502235-5 1999 When used in conjunction with aspirin and heparin, GP IIb-IIIa inhibitors have yielded favorable clinical outcomes, reducing the incidence of death, myocardial infarction, and urgent intervention. Heparin 42-49 integrin subunit alpha 2b Homo sapiens 51-57 10468150-4 1999 In patients undergoing percutaneous coronary interventions with adjunctive GPIIb/IIIa inhibition, the risk of bleeding, particularly from the femoral vascular access site, may be reduced through the use of low-dose, weight-adjusted heparin (70 U/kg), avoidance of postprocedural heparin, and early vascular sheath removal. Heparin 232-239 integrin subunit alpha 2b Homo sapiens 75-80 10695486-7 1999 In addition heparin and particular antiaggregatory drugs inhibiting platelet activation by blocking the GPIIb/IIIa receptor, the common pathway for platelet aggregation, are applied to prevent thrombus formation. Heparin 12-19 integrin subunit alpha 2b Homo sapiens 104-109 9716161-4 1998 These effects which occurred in a time-dependent manner were significant in the first 1-2 h of incubation and reached a maximum after 6 to 9 h. The GP IIb-1IIa receptor antagonist SR121566A which has been shown to block platelet aggregation induced by a wide variety of agonists including HIT serum/heparin, reduced in a dose-dependent manner the HIT serum/heparin-induced, platelet mediated expression and release of the above mentioned proteins. Heparin 299-306 integrin subunit alpha 2b Homo sapiens 148-154 10532207-3 1999 Because cross-linking of the activated platelet receptor glycoprotein (GP) IIb-IIIa by plasma fibrinogen represents the final common pathway to coronary thrombus formation, several GP IIb-IIIa inhibitors have been developed as a potentially more effective antithrombotic therapy than agents currently used for this purpose, namely aspirin and heparin. Heparin 343-350 integrin subunit alpha 2b Homo sapiens 181-187 12623570-6 1999 A number of unresolved efficacy and safety issues remain, including the duration of treatment before and after intervention; whether a reduction in the heparin dose would further decrease the risk of hemorrhage without affecting the periprocedural thrombotic rate in patients undergoing PTCA with adjunctive GPIIb/IIIa inhibitors; and the cost-effectiveness of this therapy. Heparin 152-159 integrin subunit alpha 2b Homo sapiens 308-313 9809888-6 1998 When GP IIb/IIIa inhibitors are used, weight-adjusted heparin dosing can be decreased to 70 units/kg to achieve a target ACT of 200 seconds with either the HemoTec or Hemochron device. Heparin 54-61 integrin subunit alpha 2b Homo sapiens 5-11 9716161-4 1998 These effects which occurred in a time-dependent manner were significant in the first 1-2 h of incubation and reached a maximum after 6 to 9 h. The GP IIb-1IIa receptor antagonist SR121566A which has been shown to block platelet aggregation induced by a wide variety of agonists including HIT serum/heparin, reduced in a dose-dependent manner the HIT serum/heparin-induced, platelet mediated expression and release of the above mentioned proteins. Heparin 357-364 integrin subunit alpha 2b Homo sapiens 148-154